RxDoctor Payments Data

Evan Sorett, MD

Pulmonary Disease · Great Neck, NYNPI 1386683506

Payments from drug & device makers

$17,954in general payments, 2019–2025

Across 746 payments — averaging $24.07 each. Meals, travel, consulting and speaking fees, gifts and royalties reported by drug and device makers.

  • GSK$3K
  • AstraZeneca$2K
  • Boehringer Ingelheim$2K
  • Regeneron Healthcare Solutions, Inc.$909
  • Abbott$796
  • EKOS Corporation$720
  • plus $8K from 40 others

What the payments were for

  • Travel & lodging$2041%
  • Food & beverage$17,41197%
  • Education$3392%

Most of this is food and beverage — typically meals provided during product presentations at a clinic or hospital. Nationally that is the single largest category of reported payments by count.

General payments by program year

19
20
21
22
23
24
25

Who reported the general payments

Companies are grouped under their corporate parent — a single manufacturer often files under several CMS reporting entities. Research and ownership payments are counted separately and are not in this table.

What the payments were tied to

Products named in the reported payments. Only payments of $100 or more are attributed here — the typical reported payment nationally is a meal worth about $16, and listing those product-by-product would be noise.

How this compares

$17,954 in reported general payments places this provider in the 85th percentile of 1,115 pulmonary disease providers in New York.

See all pulmonary disease providers in New York

Medicare billing

Part B allowed, 2024
$344,052
Medicare patients
775
Services billed
2,889

What this is not: this is the amount Original Medicare Part B allowed for services this provider billed in 2024. It is not their income. It excludes Medicare Advantage — now more than half of all Medicare enrollment — along with Medicaid and all commercial insurance, and it is gross practice revenue before staff, rent, supplies and malpractice premiums. CMS also suppresses any figure covering ten or fewer patients, so low-volume providers appear smaller than they are.

Most prescribed under Part D

DrugClaimsCost to plans & patients
OfevNintedanib Esylate16$274,267
Trelegy ElliptaFluticasone/Umeclidin/Vilanter131$120,255
Breo ElliptaFluticasone/Vilanterol159$85,921
Breztri AerosphereBudesonide/Glycopyr/Formoterol29$27,677
Anoro ElliptaUmeclidinium Brm/Vilanterol Tr25$15,351
EliquisApixaban27$15,231
Spiriva RespimatTiotropium Bromide16$14,280
Advair HfaFluticasone Propion/Salmeterol11$7,385
Pulmicort FlexhalerBudesonide24$5,975
SymbicortBudesonide/Formoterol Fumarate11$5,808
Wixela InhubFluticasone Propion/Salmeterol27$5,659
Fluticasone-SalmeterolFluticasone Propion/Salmeterol30$4,955
AsmanexMometasone Furoate17$4,520
Albuterol Sulfate HfaAlbuterol Sulfate113$4,231
Budesonide-Formoterol FumarateBudesonide/Formoterol Fumarate12$3,353

Paid to pharmacies, not to this prescriber.

Companies that both paid and supply prescribed drugs

These companies both reported payments to this provider and make drugs the provider prescribed under Medicare Part D in 2024. For most specialties this overlap is expected — a cardiologist who is paid by a cardiology drugmaker also treats heart disease. It is shown so the reader can see it, not because it implies anything on its own.

CompanyPaid to this providerPart D cost of their drugs
Boehringer IngelheimOfev, Spiriva Respimat$1,981$288,54832 claims
GSKTrelegy Ellipta, Breo Ellipta, Anoro Ellipta$3,337$221,526315 claims
AstraZenecaBreztri Aerosphere, Pulmicort Flexhaler, Symbicort$2,117$39,46064 claims
PfizerEliquis$19$15,23127 claims
MerckAsmanex$148$4,52017 claims

Reading this fairly. The Part D column is what drug plans and patients paid pharmacies — this provider received none of it, and it reflects how many patients they treat and what those drugs cost. Against peers, this provider's reported payments sit in the 85th percentile of 1,115 pulmonary disease providers in New York.

Other pulmonary disease in Great Neck

See the full list for New York

Where these figures come from

Is this you, or does something look wrong? →